Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

RTTNews | 566 days ago
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).

Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to developing innovative treatments for rare diseases.

Glassia is a liquid medicine for infusion containing human Alpha 1-Proteinase Inhibitor (A1-PI) also known as alpha-1 antitrypsin (A1AT), which is purified from human blood.

read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews | 512 days ago
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews | 664 days ago
Little Movement Seen For Thai Stock Market

Little Movement Seen For Thai Stock Market

The Thai stock market has finished lower in two of three trading days since the end of the four-day winning streak in which it had surged almost 50 points or 4.6 percent. The Stock Exchange of Thailand now sits just above the 1,115-point plateau and it's likely to remain rangebound again on Wednesday.
RTTNews | 17 minutes ago
Australia Building Permits Climb 3.2% On Month In May

Australia Building Permits Climb 3.2% On Month In May

The total number of building permits issued in Australia was up a seasonally adjusted 3.2 percent on month in May, the Australian Bureau of Statistics said on Wednesday - coming in at 15,212.
RTTNews | 34 minutes ago
Japanese Market Modestly Lower

Japanese Market Modestly Lower

The Japanese stock market is modestly lower on Wednesday after opening in the green, reversing the gains in the previous session, following the mixed cues from Wall Street overnight. The Nikkei 225 is falling to near the 39,600 level, with a mixed performance is most sectors.
RTTNews | 35 minutes ago